Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 51.0% in May

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Rating) was the target of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 107,000 shares, a decline of 51.0% from the April 30th total of 218,400 shares. Approximately 1.7% of the company’s shares are sold short. Based on an average daily volume of 136,800 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of Marker Therapeutics in the fourth quarter valued at about $45,000. Renaissance Technologies LLC increased its position in shares of Marker Therapeutics by 7.7% in the fourth quarter. Renaissance Technologies LLC now owns 163,200 shares of the company’s stock valued at $43,000 after acquiring an additional 11,700 shares during the period. AR Asset Management Inc. purchased a new position in shares of Marker Therapeutics in the first quarter valued at about $29,000. Finally, Raymond James & Associates purchased a new position in shares of Marker Therapeutics in the third quarter valued at about $35,000. Hedge funds and other institutional investors own 24.43% of the company’s stock.

Marker Therapeutics Stock Performance

Marker Therapeutics stock traded up $0.09 during mid-day trading on Friday, hitting $1.28. The company’s stock had a trading volume of 41,934 shares, compared to its average volume of 106,320. The business has a 50 day moving average price of $1.11 and a 200-day moving average price of $1.08. Marker Therapeutics has a 12 month low of $0.67 and a 12 month high of $6.60.

About Marker Therapeutics

(Get Rating)

Marker Therapeutics, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.